Bewersdorf, Jan Philipp http://orcid.org/0000-0003-3352-0902
Stahl, Maximilian
Taylor, Justin http://orcid.org/0000-0003-4407-6325
Mi, Xiaoli
Chandhok, Namrata Sonia
Watts, Justin
Derkach, Andriy
Wysocki, Mateusz
Lu, Sydney X.
Bourcier, Jessie http://orcid.org/0009-0008-2499-6064
Hogg, Simon J. http://orcid.org/0000-0002-3170-839X
Rahman, Jahan
Chaudhry, Sana
Totiger, Tulasigeri M.
Abdel-Wahab, Omar
Stein, Eytan M.
Article History
Received: 13 May 2023
Revised: 11 September 2023
Accepted: 21 September 2023
First Online: 9 October 2023
Competing interests
: MS has consulted for Curis Oncology, Boston Consulting and is member of the advisory board for Novartis and Kymera. OA-W has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, Prelude Therapeutics, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., AIChemy, Harmonic Discovery Inc., and Pfizer Boulder; OA-W has received prior research funding from H3B Biomedicine, Nurix, Minovia, and LOXO Oncology unrelated to the current manuscript. EMS received research funding from Bayer; was a consultant for Amgen, AbbVie, Seattle Genetics, and Biotheryx; served as a consultant and received research funding from Syndax; was a member of the Board of Directors or advisory committee for PTC Therapeutics and Syros; served as a consultant and was member of the Board of Directors or advisory committee for Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech; served as a consultant, received research funding, and was a member of the Board of Directors or advisory committee for Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis; and is a current equity holder in privately held Auron Therapeutics. None of these relationships were related to the development of this manuscript. The remaining authors declare no competing financial interests.